Washington: Dr Reddy’s Laboratories Ltd will have to wait a little longer before it can start selling a generic version of Indivior Plc’s Suboxone Film opioid addiction treatment, a US appeals court ruled on Tuesday.

The sales ban will remain in force to give Indivior time to challenge a November 20 appeals court decision it lost. In that ruling, a split 2-1 panel of the US Court of Appeals for the Federal Circuit said a trial judge was wrong to block Dr. Reddy’s from selling a generic version of Suboxone while a patent-infringement suit is pending.

Also read: Dr Reddy’s gets US FDA approval to launch Suboxone generic

The Federal Circuit said Indivior has until December 20 to file a petition for rehearing in the case, and no extensions will be granted. The court rejected a Dr. Reddy’s request that would have allowed the company to go to market immediately.

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

Close